WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Monday, May 02, 2005

Hide?	Set Name	Query	Hit Count
	DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=AND		
☐	L1	chlamyd$.ti,ab,clm.	2588
☐	L2	L1 and salmone$.ti,ab,clm.	360
☐	L3	L2 and (mammal$ or animal$ or eukaryote or eukaryotic or eucaryote or eucaryotic or cho or human or fibroblast).ti,ab,clm.	253
☐	L4	(momp or mompa or momp-a or (membrane near2 protein)).ti,ab,clm.	4958
☐	L5	L4 and l3	7
☐	L6	5770714.pn.	2
☐	L7	l1 and l4	194
☐	L8	L7 and (mammal$ or animal$ or eukaryote or eukaryotic or eucaryote or eucaryotic or cho or human or fibroblast).ti,ab,clm.	99
☐	L9	(brunham or murdin).in.	139
☐	L10	L9 and chlamyd$	109
	DB=USPT; PLUR=YES; OP=AND		
☐	L11	L9 and chlamyd$	20
☐	L12	(brunham or murdin).in.	31
☐	L13	L12 and chlamyd$	20

END OF SEARCH HISTORY

1. 6872814. 27 Oct 99; 29 Mar 05. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin; Andrew D., et al. 536/23.7; 424/184.1 424/234.1 424/263.1 435/252.3 435/320.1 435/69.3 435/71.1 435/71.2 536/23.1 536/23.4. C07H02104 C12N01500 C12N05909 A61K039118 A61K03902.

2. 6838085. 07 Jan 02; 04 Jan 05. DNA immunization against Chlamydia infection. Brunham; Robert C.. 424/263.1; 424/185.1 435/252.3 435/471 530/350 530/389.5 530/412 536/22.1 536/23.1 536/23.7. A61K039/118 A61K039/00 C07K001/00 C07H019/00 C07H021/02.

3. 6811783. 07 Sep 99; 02 Nov 04. Immunogenic compositions for protection against chlamydial infection. Murdin; Andrew D., et al. 424/190.1; 424/185.1 530/350 536/23.7. A61K039/02 A61K039/00 C07K001/00 C07H021/04.

4. 6808713. 16 Oct 01; 26 Oct 04. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin; Andrew D., et al. 424/263.1; 424/178.1 424/184.1 424/190.1 424/200.1 435/252.3 435/254.11 435/320.1 435/69.1 435/69.3 435/70.1 530/350 536/23.1 536/23.7. A61K039/118 A61K039/02 C12N001/20 C12P021/04 C07H021/04.

5. 6696421. 12 Aug 99; 24 Feb 04. DNA immunization against chlamydia infection. Brunham; Robert C.. 514/44; 424/184.1 424/263.1 435/320.1 435/69.1. A61K048/00 A61K039/00 A61K039/118 C12N015/63 C12N015/00.

6. 6693087. 20 Aug 99; 17 Feb 04. Nucleic acid molecules encoding POMP91A protein of Chlamydia. Murdin; Andrew D., et al. 514/44; 424/130.1 536/23.4. A61K039/395 A61K031/70 C07H021/04.

7. 6686339. 15 Jun 01; 03 Feb 04. Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia. Murdin; Andrew D., et al. 514/44; 424/93.2 435/320.1 536/23.1 536/23.2 536/24.1. A61K048/00 A61K035/66 C12N015/63 C07H021/04.

8. 6676949. 03 Dec 99; 13 Jan 04. Two-step immunization procedure against Chlamydia infection. Brunham; Robert C., et al. 424/263.1; 424/200.1 424/93.1 435/252.1 435/320.1 435/325 435/419 435/455 435/468 435/471 435/7.36 530/350 536/23.2 536/23.5 536/23.7 536/24.1 536/24.31 800/278 800/295 800/298. C12N015/31.

9. 6660275. 26 Jul 99; 09 Dec 03. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin; Andrew D., et al. 424/263.1; 424/184.1 424/185.1 424/190.1 435/7.36 435/89 435/91.1 435/91.31 435/91.4 435/91.42. A61K039/00 A61K039/38 A61K039/02 A61K039/118 G01N038/571.

10. 6649370. 26 Oct 99; 18 Nov 03. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin; Andrew D., et al. 435/69.1; 435/252.3 435/320.1 435/325 536/23.7. C12P021/06 C12N001/20 C12N015/00 C12N005/00 C07H021/04.

11. 6642025. 13 Jul 01; 04 Nov 03. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin; Andrew D., et al. 435/69.1; 435/320.1 435/69.3 435/69.7 435/69.8 435/71.1 435/71.2 536/23.1 536/23.7 536/24.1 536/24.2 536/24.32. C12P021/06.

12. 6635746. 28 May 99; 21 Oct 03. Chlamydial vaccines and immunogenic compositions containing an outer membrane antigen and methods of preparation thereof. Murdin; Andrew D., et al. 530/412; 530/418 530/419 530/420 530/421 530/422. A23J001/00 C07K001/00 C07K014/00

C07K016/00 C07K017/00.

☐ 13. 6632663. 22 Sep 99; 14 Oct 03. DNA immunization against chlamydia infection. Brunham; Robert C.. 435/320.1;. C12N015/63.

☐ 14. 6607730. 29 Oct 99; 19 Aug 03. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin; Andrew D., et al. 424/263.1; 424/184.1 424/185.1 424/190.1 424/200.1 424/234.1 424/278.1 435/7.36 530/389.5. A61K039/00 A61K039/38 A61K039/02 A61K039/118 A61K047/00.

☐ 15. 6521745. 20 Aug 99; 18 Feb 03. Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia. Murdin; Andrew D., et al. 536/23.1; 536/24.3. C07H021/04.

☐ 16. 6464979. 12 Sep 96; 15 Oct 02. Chlamydial vaccines and methods of preparation thereof. Murdin; Andrew D., et al. 424/184.1; 424/234.1 424/263.1. A61K039/00 A61K039/38 A61K039/02 A61K039/118.

☐ 17. 6403102. 27 Oct 99; 11 Jun 02. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin; Andrew D., et al. 424/263.1; 424/185.1 424/190.1 424/192.1 530/350. A61K039/118.

☐ 18. 6403101. 26 Oct 99; 11 Jun 02. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin; Andrew D., et al. 424/263.1; 424/185.1 424/190.1 424/192.1 530/350. A61K039/118.

☐ 19. 6344202. 07 Apr 98; 05 Feb 02. DNA immunization against chlaymdia infection. Brunham; Robert C.. 424/263.1; 424/185.1 530/350 530/389.5 530/412 536/22.1 536/23.1 536/23.7. A61K039/118 A61K039/00 C07K001/00 C07H019/00 C07H021/02.

☐ 20. 6235290. 11 Jul 97; 22 May 01. DNA immunization against chlaymdia infection. Brunham; Robert C.. 424/263.1; 424/185.1 530/350 530/389.5 530/412. A61K039/118 A61K039/00 C07K001/00 C07K016/00.

Generate Collection | Print

Terms	Documents
L12 and chlamyd$	20

20050069942. 01 Nov 04. 31 Mar 05. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin, Andrew D., et al. 435/6; 435/252.3 435/320.1 435/69.3 530/350 536/23.7 C12Q001/68 C07H021/04 C07K014/295 C12N015/74.

☐ 2. 20050065106. 10 Sep 04. 24 Mar 05. Immunogenic compositions for protection against Chlamydial infection. Murdin, Andrew D., et al. 514/44; A61K048/00.

☐ 3. 20050002960. 23 Jul 04. 06 Jan 05. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin, Andrew D., et al. 424/192.1; 435/320.1 435/325 435/69.1 530/324 536/23.5 A61K039/00 C07H021/04 C07K014/47.

☐ 4. 20050002944. 29 Dec 03. 06 Jan 05. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin, Andrew D., et al. 424/184.1; A61K039/00 A61K039/38.

☐ 5. 20040254130. 10 Apr 03. 16 Dec 04. Chlamydia antigens and corresponding dna fragments and uses thereof. Murdin, Andrew D, et al. 514/44; A61K048/00.

☐ 6. 20040228874. 14 Jan 04. 18 Nov 04. Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia. Murdin, Andrew D., et al. 424/190.1; 435/252.3 435/320.1 435/6 435/69.3 530/350 536/23.7 C12Q001/68 C07H021/04 A61K039/02.

☐ 7. 20040131630. 04 Nov 03. 08 Jul 04. Two-step immunization procedure against chlamydia infection. Brunham, Robert C., et al. 424/184.1; C12Q001/68 A61K039/00 A61K039/38.

☐ 8. 20040126382. 04 Nov 03. 01 Jul 04. Two-step immunization procedure against chlamydia infection. Brunham, Robert C., et al. 424/184.1; C12Q001/68 A61K039/00 A61K039/38.

☐ 9. 20040086525. 30 Jun 03. 06 May 04. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin, Andrew D., et al. 424/190.1; 435/252.3 435/320.1 435/69.3 530/350 536/23.7 C07H021/04 A61K039/02 C12N001/21 C07K014/295.

☐ 10. 20040022801. 28 Jan 03. 05 Feb 04. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin, Andrew D., et al. 424/190.1; 435/252.3 435/320.1 435/6 435/69.7 530/350 536/23.7 A61K039/02 C12Q001/68 C07H021/04 C12P021/04 C12N001/21 C07K014/295.

☐ 11. 20030225017. 30 Dec 02. 04 Dec 03. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin, Andrew D., et al. 514/44; 424/185.1 435/252.3 435/320.1 435/6 435/69.3 530/350 536/23.2 A61K048/00 C12Q001/68 C07H021/04 A61K039/00 C12N001/21 C12P021/02 C07K014/195.

☐ 12. 20030224004. 06 Feb 03. 04 Dec 03. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin, Andrew D., et al. 424/184.1; A61K039/00 A61K039/38.

☐ 13. 20030206921. 07 Jan 03. 06 Nov 03. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin, Andrew D., et al. 424/190.1; 435/252.3 435/320.1 435/6 435/69.3 530/350 530/388.4 536/23.7 C12Q001/68 C07H021/04 A61K039/02 C12N001/21 C07K014/295 C07K016/12.

☐ 14. 20030170259. 27 Oct 99. 11 Sep 03. CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF. MURDIN, ANDREW D., et al. 424/190.1; A61K039/02.

☐ 15. 20030161833. 31 Dec 02. 28 Aug 03. Chlamydia antigens and corresponding DNA fragments

and uses thereof. Murdin, Andrew D., et al. 424/184.1; 536/23.1 C07H021/02 C07H021/04 A61K039/00 A61K039/38.

☐ 16. 20030157124. 20 Dec 02. 21 Aug 03. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin, Andrew D., et al. 424/190.1; 435/252.3 435/320.1 435/69.3 530/350 536/23.7 A61K039/02 C07H021/04 C07K014/295 C12P021/02 C12N001/21 C12N015/74.

☐ 17. 20030157123. 17 Dec 02. 21 Aug 03. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin, Andrew D., et al. 424/190.1; 435/252.3 435/320.1 435/69.3 514/44 530/350 536/23.7 A61K048/00 C07H021/04 A61K039/02 C12P021/02 C12N001/21 C07K014/295.

☐ 18. 20030147924. 26 Jul 99. 07 Aug 03. CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USESTHEREOF. MURDIN, ANDREW D., et al. 424/263.1; 435/252.3 435/320.1 435/69.3 530/350 536/23.7 A61K039/118 C07H021/04 C12P021/02 C12N001/21 C07K014/295 C12N015/74.

☐ 19. 20030100706. 03 Apr 01. 29 May 03. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin, Andrew D., et al. 530/350; 424/190.1 536/23.7 A61K039/02 A61K048/00 C07H021/04 C07K014/195.

☐ 20. 20030095973. 03 May 00. 22 May 03. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin, Andrew D., et al. 424/184.1; A61K039/40 A61K039/00 A61K039/38.

☐ 21. 20020168382. 03 Dec 99. 14 Nov 02. TWO-STEP IMMUNIZATION PROCEDURE AGAINST CHLAMYDIA INFECTION. Brunham, Robert C., et al. 424/200.1; A61K039/02.

☐ 22. 20020150591. 26 Jul 99. 17 Oct 02. CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF. MURDIN, ANDREW D., et al. 424/190.1; A61K039/02.

☐ 23. 20020142001. 07 Jan 02. 03 Oct 02. DNA immunization against Chlaymdia infection. Brunham, Robert C.. 424/184.1; A61K039/00 A61K039/38.

☐ 24. 20020132994. 03 Apr 01. 19 Sep 02. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin, Andrew D., et al. 536/23.1; C07H021/02 C07H021/04 A61K048/00.

☐ 25. 20020123067. 22 Dec 00. 05 Sep 02. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin, Andrew D., et al. 435/7.1; 424/184.1 530/350 G01N033/53 A61K039/00 A61K039/38 C07K001/00 C07K014/00 C07K017/00.

☐ 26. 20020110542. 12 Aug 99. 15 Aug 02. DNA IMMUNIZATION AGAINST CHLAMYDIA INFECTION. BRUNHAM, ROBERT C.. 424/93.2; 424/263.1 424/93.21 435/320.1 435/69.1 514/44 A61K048/00 A61K039/118.

☐ 27. 20020102270. 08 Feb 01. 01 Aug 02. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin, Andrew D., et al. 424/190.1; 435/183 435/252.3 435/320.1 435/69.3 514/44 536/23.7 A61K048/00 C07H021/04 C12N009/00 A61K039/02 C12N001/21 C12P021/02.

☐ 28. 20020099188. 22 Dec 00. 25 Jul 02. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin, Andrew D., et al. 536/23.1; C07H021/02 C07H021/04.

☐ 29. 20020094965. 03 Apr 01. 18 Jul 02. Chlamydia antigens and corresponding DNA fragments

and uses thereof. Murdin, Andrew D., et al. 514/44; 536/23.2 536/23.5 A61K048/00 C07H021/04.

☐ 30. 20020094340. 01 Dec 99. 18 Jul 02. CHLAMYDIA ANTIGENS AND CORRESPONDING DNA THEREOF. MURDIN, ANDREW D., et al. 424/263.1; A61K039/118.

☐ 31. 20020091096. 13 Jul 01. 11 Jul 02. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin, Andrew D., et al. 514/44; 435/252.3 435/320.1 435/6 435/69.1 435/91.2 536/23.7 A61K048/00 C12Q001/68 C07H021/04 C12P021/02 C12N001/21.

☐ 32. 20020082402. 03 Apr 01. 27 Jun 02. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin, Andrew D., et al. 536/23.1; 424/184.1 530/350 C07H021/02 C07H021/04 A61K039/00 A61K039/38 C07K001/00 C07K014/00 C07K017/00.

☐ 33. 20020081682. 28 Jun 01. 27 Jun 02. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin, Andrew D., et al. 435/183; 424/263.1 435/252.3 435/320.1 435/69.3 536/23.7 C12N009/00 C07H021/04 A61K039/118 C12N001/21 C12P021/02 C12N015/74.

☐ 34. 20020071831. 03 Apr 01. 13 Jun 02. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin, Andrew D., et al. 424/93.21; 424/185.1 435/183 435/320.1 435/325 435/69.1 514/44 536/23.2 A61K048/00 C07H021/04 C12P021/02 C12N005/06 C12N009/00.

☐ 35. 20020037293. 22 Jun 01. 28 Mar 02. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin, Andrew D., et al. 424/190.1; 424/263.1 435/252.3 435/320.1 435/69.3 536/23.7 A61K039/118 C07H021/04 C12N001/21 C12P021/02 C12N015/74.

☐ 36. 6872814. 27 Oct 99; 29 Mar 05. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin; Andrew D., et al. 536/23.7; 424/184.1 424/234.1 424/263.1 435/252.3 435/320.1 435/69.3 435/71.1 435/71.2 536/23.1 536/23.4. C07H02104 C12N01500 C12N05909 A61K039118 A61K03902.

☐ 37. 6838085. 07 Jan 02; 04 Jan 05. DNA immunization against Chlamydia infection. Brunham; Robert C.. 424/263.1; 424/185.1 435/252.3 435/471 530/350 530/389.5 530/412 536/22.1 536/23.1 536/23.7. A61K039/118 A61K039/00 C07K001/00 C07H019/00 C07H021/02.

☐ 38. 6811783. 07 Sep 99; 02 Nov 04. Immunogenic compositions for protection against chlamydial infection. Murdin; Andrew D., et al. 424/190.1; 424/185.1 530/350 536/23.7. A61K039/02 A61K039/00 C07K001/00 C07H021/04.

☐ 39. 6808713. 16 Oct 01; 26 Oct 04. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin; Andrew D., et al. 424/263.1; 424/178.1 424/184.1 424/190.1 424/200.1 435/252.3 435/254.11 435/320.1 435/69.1 435/69.3 435/70.1 530/350 536/23.1 536/23.7. A61K039/118 A61K039/02 C12N001/20 C12P021/04 C07H021/04.

☐ 40. 6696421. 12 Aug 99; 24 Feb 04. DNA immunization against chlamydia infection. Brunham; Robert C.. 514/44; 424/184.1 424/263.1 435/320.1 435/69.1. A61K048/00 A61K039/00 A61K039/118 C12N015/63 C12N015/00.

☐ 41. 6693087. 20 Aug 99; 17 Feb 04. Nucleic acid molecules encoding POMP91A protein of Chlamydia. Murdin; Andrew D., et al. 514/44; 424/130.1 536/23.4. A61K039/395 A61K031/70 C07H021/04.

☐ 42. 6686339. 15 Jun 01; 03 Feb 04. Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia. Murdin; Andrew D., et al. 514/44; 424/93.2 435/320.1 536/23.1 536/23.2 536/24.1. A61K048/00 A61K035/66 C12N015/63 C07H021/04.

☐ 43. 6676949. 03 Dec 99; 13 Jan 04. Two-step immunization procedure against Chlamydia infection. Brunham; Robert C., et al. 424/263.1; 424/200.1 424/93.1 435/252.1 435/320.1 435/325 435/419 435/455 435/468 435/471 435/7.36 530/350 536/23.2 536/23.5 536/23.7 536/24.1 536/24.31 800/278 800/295 800/298. C12N015/31.

☐ 44. 6660275. 26 Jul 99; 09 Dec 03. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin; Andrew D., et al. 424/263.1; 424/184.1 424/185.1 424/190.1 435/7.36 435/89 435/91.1 435/91.31 435/91.4 435/91.42. A61K039/00 A61K039/38 A61K039/02 A61K039/118 G01N038/571.

☐ 45. 6649370. 26 Oct 99; 18 Nov 03. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin; Andrew D., et al. 435/69.1; 435/252.3 435/320.1 435/325 536/23.7. C12P021/06 C12N001/20 C12N015/00 C12N005/00 C07H021/04.

☐ 46. 6642025. 13 Jul 01; 04 Nov 03. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin; Andrew D., et al. 435/69.1; 435/320.1 435/69.3 435/69.7 435/69.8 435/71.1 435/71.2 536/23.1 536/23.7 536/24.1 536/24.2 536/24.32. C12P021/06.

☐ 47. 6635746. 28 May 99; 21 Oct 03. Chlamydial vaccines and immunogenic compositions containing an outer membrane antigen and methods of preparation thereof. Murdin; Andrew D., et al. 530/412; 530/418 530/419 530/420 530/421 530/422. A23J001/00 C07K001/00 C07K014/00 C07K016/00 C07K017/00.

☐ 48. 6632663. 22 Sep 99; 14 Oct 03. DNA immunization against chlamydia infection. Brunham; Robert C.. 435/320.1;. C12N015/63.

☐ 49. 6607730. 29 Oct 99; 19 Aug 03. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin; Andrew D., et al. 424/263.1; 424/184.1 424/185.1 424/190.1 424/200.1 424/234.1 424/278.1 435/7.36 530/389.5. A61K039/00 A61K039/38 A61K039/02 A61K039/118 A61K047/00.

☐ 50. 6521745. 20 Aug 99; 18 Feb 03. Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia. Murdin; Andrew D., et al. 536/23.1; 536/24.3. C07H021/04.

Generate Collection Print

Terms	Documents
L9 and chlamyd$	109

Prev Page Next Page Go to Doc#

6464979. 12 Sep 96; 15 Oct 02. Chlamydial vaccines and methods of preparation thereof. Murdin; Andrew D., et al. 424/184.1; 424/234.1 424/263.1. A61K039/00 A61K039/38 A61K039/02 A61K039/118.

☐ 52. 6403102. 27 Oct 99; 11 Jun 02. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin; Andrew D., et al. 424/263.1; 424/185.1 424/190.1 424/192.1 530/350. A61K039/118.

☐ 53. 6403101. 26 Oct 99; 11 Jun 02. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin; Andrew D., et al. 424/263.1; 424/185.1 424/190.1 424/192.1 530/350. A61K039/118.

☐ 54. 6344202. 07 Apr 98; 05 Feb 02. DNA immunization against chlaymdia infection. Brunham; Robert C.. 424/263.1; 424/185.1 530/350 530/389.5 530/412 536/22.1 536/23.1 536/23.7. A61K039/1 18 A61K039/00 C07K001/00 C07H019/00 C07H021/02.

☐ 55. 6235290. 11 Jul 97; 22 May 01. DNA immunization against chlaymdia infection. Brunham; Robert C.. 424/263.1; 424/185.1 530/350 530/389.5 530/412. A61K039/118 A61K039/00 C07K001/00 C07K016/00.

☐ 56. WO002095413A2. 23 May 02. 28 Nov 02. PHAGE HOST <i>CHLAMYDIA<;/i> INVOLVED IN VASCULAR DISEASE. BRUNHAM, ROBERT C, et al. G01N033/68; G01N033/569 C12Q001/68 C12N015/10.

☐ 57. WO009810789A1. 11 Sep 97. 19 Mar 98. CHLAMYDIAL VACCINES AND IMMUNOGENIC COMPOSITIONS CONTAINING AN OUTER MEMBRANE ANTIGEN AND METHODS OF PREPARATION THEREOF. MURDIN, ANDREW D, et al. A61K039/118; C07K014/295.

☐ 58. WO009802546A2. 11 Jul 97. 22 Jan 98. DNA IMMUNIZATION AGAINST CHLAMYDIA INFECTION. BRUNHAM, ROBERT C. C12N015/31; A61K031/70 C07K014/295 A61K039/118.

☐ 59. WO009426900A2. 12 May 94. 24 Nov 94. HYBRID PICORNAVIRUSES EXPRESSING CHLAMYDIAL EPITOPES. MURDIN, ANDREW DAVID, et al. C12N015/31; C12N007/00 C12N015/86 A61K039/118 A61K039/13 C12P021/08 G01N033/571 C12N015/62.

☐ 60. US20050065106A. New immunogenic composition comprising a major outer membrane protein, a 76-kDa protein, and a pharmaceutical carrier, useful for preventing and treating Chlamydial infection. DUNN, P L, et al. A61K048/00.

☐ 61. US 6811783B. New immunogenic composition comprises a major outer membrane protein of a strain of Chlamydia pneumoniae, and a 76 kDa protein of a strain of C. pneumoniae, useful as a vaccine for treating or preventing Chlamydia infections. DUNN, P L, et al. A61K039/00 A61K039/02 C07H021/04 C07K001/00.

☐ 62. WO 200295413A. Method for identifying a subject susceptible to vascular disease (e.g. abdominal aortic aneurysm) by detecting the presence or absence of a bacteriophage Phi Cpn1 host Chlamydia component in the sample, or an antibody to the component. BLANCHARD, J, et al. C12N015/10 C12Q001/68 G01N033/569 G01N033/68.

☐ 63. WO 200185972A. Vaccine useful for immunizing mammals against chlamydia infections,

comprises vectors having sequences of ATP binding cassette gene, secretary locus open reading frame gene of chlamydia. DUNN, P, et al. A61K039/118 A61K039/40 A61K048/00 C07K016/12 C07K019/00 C12N015/85.

☐ 64. US20020082402A. Novel polypeptides from Chlamydia pneumoniae and genes encoding the polypeptide, useful for immunization of host e.g. human against disease caused by infection by a strain of Chlamydia. DUNN, P, et al. A61K039/00 A61K039/118 A61K039/38 A61K039/40 C07H021/02 C07H021/04 C07K001/00 C07K014/00 C07K014/295 C07K016/12 C07K017/00 C12N015/11 C12N015/31 C12N015/62 C12Q001/68 G01N033/53 G01N033/68.

☐ 65. WO 200175113A. Novel Chlamydia myosin heavy chain homolog polypeptide and polynucleotide for preventing, detecting and treating Chlamydia infections in mammals, in particular humans. DUNN, P, et al. A61K039/118 A61K039/40 A61K048/00 C07H021/02 C07H021/04 C07K014/295 C07K016/12 C12N015/11 C12N015/31 C12N015/62 C12Q001/68 G01N033/53 G01N033/68.

☐ 66. US20020094965A. Novel Chlamydia glutamate binding protein and polynucleotide for preventing, detecting and treating Chlamydia infections in mammals, in particular humans. DUNN, P, et al. A61K039/118 A61K039/40 A61K048/00 C07H021/04 C07K014/295 C07K016/12 C07K019/00 C12N001/21 C12N015/31 C12N015/62 C12N015/74 C12Q001/68 G01N033/569.

☐ 67. WO 200175111A. Novel isolated myosin heavy chain polypeptide from Chlamydia pneumoniae and polynucleotides encoding them, useful for treating or preventing Chlamydia infection in mammals. DUNN, P, et al. A61K039/02 A61K039/118 A61K039/40 A61K048/00 C07H021/04 C07K014/195 C07K014/295 C07K016/12 C07K019/00 C12N001/21 C12N015/31 C12N015/62 C12N015/74 C12Q001/68 G01N033/569.

☐ 68. US20020071831A. Novel Chlamydia ATP-binding cassette and corresponding DNA molecule for preventing, diagnosing and treating Chlamydia infections in mammals, in particular humans. DUNN, P, et al. A61K038/16 A61K039/02 A61K048/00 C07H021/04 C07K014/295 C07K016/12 C12N001/21 C12N005/06 C12N009/00 C12P021/02 C12Q001/68.

☐ 69. WO 200146226A. Chlamydia polypeptides, designated membrane ATPase and corresponding DNA molecules for preventing, diagnosing and treating Chlamydia infection in mammals, including humans. DUNN, P, et al. A61K039/00 A61K048/00 C07H021/04 C07K014/00 C07K014/195 C12N001/21 C12P021/02 C12Q001/68.

☐ 70. US20020099188A. Chlamydia outer membrane protein and corresponding DNA molecules for preventing, diagnosing and treating Chlamydia infection in mammals, such as humans. DUNN, P, et al. C07H021/02 C07H021/04 C07K014/00.

☐ 71. US20020123067A. Chlamydia polypeptides and polynucleotides for preventing, diagnosing and treating Chlamydia infection in mammals, especially humans. DUNN, P, et al. A61K038/16 A61K039/00 A61K039/118 A61K039/38 A61K048/00 C07H021/02 C07H021/04 C07K001/00 C07K014/00 C07K014/295 C07K016/12 C07K017/00 C07K019/00 C12N001/15 C12N001/19 C12N001/21 C12N005/10 C12N015/09 C12N015/31 C12N015/62 C12N015/63 C12P021/02 C12Q001/68 G01N033/15 G01N033/50 G01N033/53 G01N033/566.

☐ 72. WO 200136455A. Novel Chlamydia pneumoniae membrane ATPase polypeptide useful for preventing, treating or detecting Chlamydia infection. DUNN, P, et al. A61K039/02 A61K048/00 C07H021/04 C07K014/00 C07K014/295 C12N001/21 C12P021/02.

☐ 73. WO 200136457A. A Chlamydia polypeptide, an amino acid transporter gene, for the treatment and prevention of Chlamydia infection. DUNN, P, et al. C07K014/00.

☐ 74. WO 200136456A. A Chlamydia polypeptide, OppB, for the treatment and prevention of Chlamydia infection. DUNN, P, et al. C07K014/00.

☐ 75. US 6235290B. DNA Immunization against Chlamydia is useful for generating a protective immune response and treating chlamydial infections of the lung, especially Chlamydia trachomatis. BRUNHAM, R C. A61K039/00 A61K039/118 C07K001/00 C07K016/00.

☐ 76. WO 200121810A. New lpxB polypeptides useful for treating, preventing or diagnosing Chlamydia infections, particularly infections caused by Chlamydia pneumonia, e.g. bronchitis, cough, asthma. DUNN, P, et al. A61K031/711 A61K038/45 A61K039/40 C07K016/40 C12N009/10 C12N015/54 C12N015/62 C12N015/85 G01N033/53.

☐ 77. WO 200121805A. New general secretion pathway protein E polypeptides and nucleic acids encoding the polypeptides useful for treating, preventing or diagnosing Chlamydia infections, particularly infections caused by Chlamydia pneumoniae. DUNN, P, et al. A61K031/711 A61K039/118 A61K039/40 C07K014/295 C07K016/12 C12N015/31 C12N015/62 C12N015/85 G01N033/53.

☐ 78. WO 200121803A. New Npt2cp (ADP/ATP translocase) polypeptides and nucleic acids encoding the polypeptides useful for treating, preventing or diagnosing Chlamydia infections, particularly infections caused by Chlamydia pneumoniae. DUNN, P, et al. A61K031/711 A61K039/118 A61K039/40 C07K014/295 C07K016/12 C12N015/31 C12N015/62 C12N015/85 G01N033/53.

☐ 79. WO 200121811A. New non-replicating vector comprising a Chlamydia trachomatis serine threonine kinase gene is useful as a DNA vaccine against chlamydial infection, e.g. lung infection caused by C. trachomatis or C. pneumoniae. BRUNHAM, R C. A61K031/711 C12N015/54 C12N015/63 C12N015/85.

☐ 80. WO 200121806A. Novel Chlamydia pneumoniae hypothetical apoptosis inhibitor antigen and polynucleotides encoding them useful as component of vaccines for treating Chlamydia infections, and for detecting Chlamydia infection. DUNN, P, et al. A61K031/711 A61K039/118 A61K039/40 C07K014/295 C07K016/12 C12N015/31 C12N015/62 C12N015/85 G01N033/53.

☐ 81. WO 200121802A. Novel Chlamydia pneumoniae lpdA protein and polynucleotides encoding them useful as component of vaccines for treating Chlamydia infections, and for detecting Chlamydia infection in the body fluid of a mammal. DUNN, P, et al. A61K039/118 C07K014/295 C07K016/12 C07K019/00 C12N005/10 C12N015/31 C12N015/62 C12N015/63 C12Q001/68 G01N033/53.

☐ 82. WO 200121804A. Novel Chlamydia pneumoniae outer membrane protein and polynucleotides encoding them, useful as components of vaccines for treating Chlamydia infections, and for detecting Chlamydia infections in the body fluids of mammals. DUNN, P, et al. A61K031/711 A61K035/76 A61K038/00 A61K039/00 A61K039/118 A61K039/38 A61K039/395 A61K039/40 A61K048/00 A61P011/00 A61P031/00 C07K014/295 C07K016/12 C07K019/00 C12N001/15 C12N001/19 C12N001/21 C12N005/10 C12N015/09 C12N015/31 C12N015/62 C12N015/85 C12P021/02 C12Q001/68 G01N033/15 G01N033/50 G01N033/53 G01N033/566 G01N033/569 C12P021/02 C12R001:01.

☐ 83. WO 200102575A. New orfF nucleic acids and polypeptides from Chlamydia, useful as a

vaccine for treating or preventing Chlamydia infections, specifically Chlamydia pneumoniae. DUNN, P, et al. A61K031/711 A61K039/118 A61K039/40 C07K014/295 C07K016/12 C12N015/31 C12N015/62 C12N015/85 G01N033/53.

☐ 84. WO 200066739A. Nucleic acids encoding a 76 kDa protein from Chlamydia pneumoniae, useful for vaccinating against Chlamydia infections. DUNN, P, et al. A61K031/70 A61K039/00 A61K039/02 A61K039/118 A61K039/38 A61K039/39 A61K039/395 A61K039/40 A61K048/00 A61P009/10 A61P011/00 A61P011/02 A61P011/06 A61P031/04 C07H021/04 C07K014/295 C07K016/12 C07K019/00 C12N001/15 C12N001/19 C12N001/21 C12N005/10 C12N015/09 C12N015/11 C12N015/31 C12N015/62 C12N015/85 C12P021/02 C12Q001/68 G01N033/53 G01N033/566 G01N033/569.

☐ 85. WO 200055326A. New polynucleotides encoding a 60kda cysteine-rich membrane protein from Chlamydia, useful as a vaccine for preventing and treating Chlamydia infection in mammals. DUNN, P, et al. A61K031/711 A61K038/00 A61K039/02 A61K039/118 A61K039/395 A61K048/00 A61P011/00 A61P031/04 C07H021/04 C07K014/295 C07K016/12 C07K019/00 C12N001/15 C12N001/19 C12N001/21 C12N005/10 C12N015/09 C12N015/31 C12N015/62 C12N015/74 C12P021/02 C12Q001/04 C12Q001/68 C12Q001/70 G01N033/569.

☐ 86. WO 200053764A. Polynucleotides encoding 9 kDa cysteine-rich membrane protein from chlamydia, useful as a vaccine for preventing and treating chlamydia infection in mammals. DUNN, P, et al. A61K039/02 C07K014/295 C07K016/12 C12N015/31 C12N015/62 C12Q001/04 C12Q001/70 E01C019/22 E01C019/48 E04F021/24.

☐ 87. US 6460006B. Compaction performance predicting method for information system involves predicting number of passes by compaction machine required to reach desired material density value. CORCORAN, P T, et al. A61K039/118 E01C019/28 G01N009/36 G06F015/00.

☐ 88. US20020037293A. Novel Chlamydia polynucleotides and polypeptides useful for diagnosis, prevention and treatment of Chlamydia infection in mammals. MURDIN, A D, et al. A61K031/711 A61K038/00 A61K038/16 A61K039/118 A61K039/395 A61K045/00 A61K048/00 A61P031/04 C07H021/04 C07K014/295 C07K016/12 C07K019/00 C12N001/15 C12N001/19 C12N001/21 C12N005/10 C12N015/09 C12N015/31 C12N015/62 C12N015/74 C12P021/00 C12P021/02 C12Q001/68 G01N033/15 G01N033/50 G01N033/53 G01N033/566 G01N033/569.

☐ 89. US20020081682A. Novel Chlamydia polynucleotides and polypeptides, useful for diagnosis, prevention and treatment of Chlamydia infection in mammals. DUNN, P, et al. A61K031/7088 A61K038/16 A61K038/45 A61K039/00 A61K039/02 A61K039/118 A61K039/39 A61K039/395 A61K048/00 A61P011/00 A61P031/00 C07H021/04 C07K014/295 C07K014/47 C07K016/12 C07K019/00 C12N001/15 C12N001/19 C12N001/20 C12N001/21 C12N005/10 C12N009/00 C12N009/12 C12N015/09 C12N015/31 C12N015/62 C12N015/74 C12P021/00 C12P021/02 C12P021/04 C12Q001/68 G01N033/15 G01N033/50 G01N033/53 G01N033/569.

☐ 90. WO 200034498A. Vaccination against diseases caused by Chlamydia infection involves initial administration of attenuated bacteria containing nucleic acid encoding Chlamydia protein, followed by administration of Chlamydia protein. BRUNHAM, R C, et al. A61K031/70 A61K035/74 A61K035/76 A61K038/00 A61K039/00 A61K039/02 A61K039/112 A61K039/118 A61K039/38 A61K048/00 A61P015/00 A61P027/02 A61P031/04 C12N001/20 C12N001/21 C12N001:21 C12N015/09 C12N015/31 C12N015/86 C12N015/87 C12Q001/68 C12R001:42 C12N001/21 C12R001:42 C12R001:42 C12N001/21.

☐ 91. US20020123517A. Nucleic acids encoding polypeptide antigens from Chlamydia useful for preventing, diagnosing and treating diseases such as community acquired pneumonia, bronchitis, sinusitis and asthmatic bronchitis, adult-onset asthma. MURDIN, A D, et al. A61K031/44 A61K031/7088 A61K039/118 A61K039/385 A61K039/39 A61K039/395 A61K048/00 A61P031/00 C07K007/08 C07K014/295 C07K014/705 C07K016/12 C07K019/00 C12N001/15 C12N001/19 C12N001/21 C12N005/10 C12N015/00 C12N015/62 C12P021/02 C12Q001/68 G01N033/15 G01N033/50 G01N033/53 G01N033/569.

☐ 92. US20020094340A. New polynucleotide encoding the Chlamydia 98 kiloDalton outer membrane protein, useful for preventing or treating Chlamydia infection. DUNN, P, et al. A61K031/711 A61K038/00 A61K039/02 A61K039/118 A61K039/39 A61K039/395 A61K048/00 A61P031/04 C07H021/04 C07K014/295 C07K014/705 C07K016/12 C07K019/00 C12N001/15 C12N001/19 C12N001/21 C12N005/10 C12N015/09 C12N015/11 C12N015/31 C12N015/62 C12N015/63 C12N015/74 C12P021/02 C12Q001/68 G01N033/15 G01N033/50 G01N033/53 G01N033/569.

☐ 93. US 6403102B. Novel Chlamydia PilG-like protein antigen, used for vaccination and protection against Chlamydia infection. DUNN, P L, et al. A61K038/00 A61K039/00 A61K039/02 A61K039/118 A61K048/00 A61P031/04 C07K014/295 C07K016/12 C07K019/00 C12N001/15 C12N001/19 C12N001/21 C12N005/10 C12N015/09 C12N015/31 C12N015/62 C12P021/02 C12P021/08 C12Q001/68 G01N033/543 G01N033/569 G01N033/571 G01N033/577 C12Q001/68 C12R001:01.

☐ 94. WO 200026239A. Novel Chlamydia POMP91B precursor protein antigen, used for vaccination and protection against Chlamydia infection. DUNN, P L, et al. A61K031/7088 A61K039/00 A61K039/02 A61K039/118 A61K039/38 A61K039/39 A61K047/00 A61P009/10 A61P011/00 A61P011/06 A61P031/00 C07H021/04 C07K001/22 C07K014/00 C07K014/295 C07K016/12 C07K019/00 C12N001/15 C12N001/19 C12N001/21 C12N005/10 C12N015/09 C12N015/31 C12P021/02 C12P021/04 C12P021/08 C12Q001/68 G01N033/53 G01N033/566 G01N033/569 G01N033/577.

☐ 95. WO 200026237A. Novel Chlamydia 98 kDa putative outer membrane protein antigen, used for vaccination and protection against Chlamydia infection. DUNN, P L, et al. A61K031/70 A61K035/74 A61K035/76 A61K039/02 A61K039/118 A61K039/385 A61K039/39 A61K048/00 A61P031/00 C07H021/04 C07K014/00 C07K014/295 C07K016/12 C07K019/00 C12N001/15 C12N001/19 C12N001/21 C12N005/10 C12N015/00 C12N015/09 C12N015/31 C12P021/02 C12P021/08 C12Q001/68 G01N033/15 G01N033/50 G01N033/566 G01N033/569 G01N033/577.

☐ 96. US20020102270A. Isolated polynucleotide encoding a Chlamydia polypeptide useful to treat, diagnose and prevent disease caused by Chlamydia infection. DUNN, P L, et al. A61K039/02 A61K039/118 A61K039/395 A61K048/00 A61P011/00 A61P011/06 A61P031/04 C07H021/04 C07K001/22 C07K014/295 C07K016/12 C07K019/00 C12N001/15 C12N001/19 C12N001/20 C12N001/21 C12N005/00 C12N005/10 C12N009/00 C12N015/00 C12N015/09 C12N015/31 C12N015/62 C12P021/02 C12P021/06 C12P021/08 C12Q001/68 G01N033/53 G01N033/566 G01N033/569 G01N033/577 C12N001/21 C12N015/09 C12P021/02 C12R001:01 C12R001:01 C12R001:01.

☐ 97. US 6403101B. Isolated polynucleotide encoding a Chlamydia polypeptide useful to treat, diagnose and prevent disease caused by Chlamydia infection. DUNN, P L, et al. A61K038/00 A61K039/00 A61K039/02 A61K039/118 A61K039/39 A61K048/00 A61P009/10 A61P011/00 A61P011/06 C07H021/04 C07K001/22 C07K014/295 C07K016/12 C12N001/15 C12N001/19 C12N001/21 C12N005/10 C12N015/09 C12N015/31 C12N015/62 C12P021/02 C12P021/06

C12Q001/68 G01N033/53 G01N033/543 G01N033/566 G01N033/569 C12N001/21 C12N015/09 C12P021/02 C12R001:01 C12R001:01 C12R001:01.

☐ 98. WO 200024765A. Chlamydia antigenes and the proteins they encode, useful for vaccinating against Chlamydia infections that affect the respiratory tract. MURDIN, A D, et al. A61K038/00 A61K039/118 A61K039/395 A61K048/00 A61P031/04 C07K014/00 C07K014/295 C07K016/12 C12N001/15 C12N001/19 C12N001/21 C12N005/10 C12N015/09 C12N015/62 C12Q001/68 G01N033/15 G01N033/50 G01N033/53 G01N033/569.

☐ 99. WO 200011183A. Novel antigens and corresponding DNA molecules that can be used to prevent, treat and diagnose disease caused by Chlamydia infection in mammals, especially humans. MURDIN, A D, et al. A61K031/713 A61K035/76 A61K039/118 A61K039/39 A61P031/04 C07K014/295 C07K016/12 C12N001/15 C12N001/19 C12N001/21 C12N005/10 C12N015/09 C12N015/31 C12P021/02 C12P021/08 C12Q001/68 G01N033/15 G01N033/50 G01N033/566 G01N033/569 G01N033/577.

☐ 100. WO 200011181A. Nucleic acid molecule encoding an inclusion membrane protein C of a strain of Chlamydia, useful as a vaccine for immunizing against Chlamydia infection. DUNN, P L, et al. A61K035/66 A61K039/02 A61K039/118 A61K048/00 C07H021/04 C07K014/295 C07K016/12 C12N015/31 C12N015/63 C12Q001/68.

Generate Collection Print

Terms	Documents
L9 and chlamyd$	109

Prev Page Next Page Go to Doc#

101. WO 200011180A. New nucleic acid encoding POMP91A protein from a strain of Chlamydia useful for preventing, treating and diagnosing Chlamydia infection. DUNN, P L, et al. A61K031/70 A61K039/395 A61K048/00 C07H021/04 C07K014/295 C12N015/31.

☐ 102. WO 200006742A. Chlamydia pneumoniae antigens used for immunization and protection against Chlamydia diseases. MURDIN, A D, et al. A61K031/711 A61K039/00 A61K039/02 A61K039/118 A61K039/38 A61K039/385 A61K048/00 A61P031/04 C07K001/22 C07K014/295 C07K016/12 C07K019/00 C12N001/15 C12N001/19 C12N001/21 C12N005/10 C12N015/09 C12N015/31 C12N015/62 C12P021/02 C12P021/08 C12Q001/68 G01N033/53 G01N033/569 G01N033/571 G01N033/577.

☐ 103. WO 200006740A. Novel Chlamydia pneumoniae antigens used for immunization and protection against Chlamydia diseases. MURDIN, A D, et al. A61K039/02 A61K039/118 A61K048/00 A61P031/04 C07H021/04 C07K001/22 C07K014/295 C07K016/12 C07K019/00 C12N001/15 C12N001/19 C12N001/21 C12N005/10 C12N015/09 C12N015/31 C12N015/62 C12N015/74 C12P021/02 C12P021/08 C12Q001/68 G01N033/53 G01N033/543 G01N033/566 G01N033/569 G01N033/577.

☐ 104. WO 200006743A. Chlamydia pneumoniae antigens used for immunization and protection against Chlamydia diseases. DUNN, P L, et al. A61K038/00 A61K039/118 A61K048/00 A61P011/00 A61P011/06 A61P013/00 A61P027/02 A61P031/04 C07K001/22 C07K014/295 C07K016/12 C12N001/15 C12N001/19 C12N001/21 C12N005/10 C12N015/09 C12N015/31 C12N015/62 C12P021/02 C12Q001/68 G01N033/53 G01N033/537 G01N033/566 G01N033/569 G01N033/577.

☐ 105. WO 200006741A. Novel polynucleotides and Chlamydia pneumoniae outer membrane protein encoded by them for use as vaccines in treating and diagnosing chlamydial infections. DUNN, P L, et al. A61K031/70 A61K039/00 A61K039/118 C07K001/22 C07K014/295 C07K016/12 C07K019/00 C12N001/15 C12N001/19 C12N001/21 C12N005/10 C12N015/09 C12N015/31 C12N015/62 C12P021/02 C12P021/08 C12Q001/04 C12Q001/68 G01N033/15 G01N033/50 G01N033/566 G01N033/569 G01N033/577.

☐ 106. WO 200006739A. Novel Chlamydia pneumoniae antigens used for immunization and protection against Chlamydia diseases. MURDIN, A D, et al. A61K039/02 A61K039/118 A61K039/39 A61K048/00 A61P031/04 C07K001/22 C07K014/295 C07K016/12 C07K019/00 C12N001/15 C12N001/19 C12N001/21 C12N005/10 C12N015/09 C12N015/31 C12N015/62 C12P021/02 C12Q001/68 G01N033/53 G01N033/543 G01N033/566 G01N033/569 G01N033/577 C12Q001/68 C12R001:01.

☐ 107. US 6464979B. New immunogenic Chlamydia compositions - comprising an outer membrane antigen extract of Chlamydia and an immunostimulating complex. MURDIN, A D, et al. A23J001/00 A61K039/00 A61K039/02 A61K039/118 A61K039/38 C07K001/00 C07K014/00 C07K014/295 C07K016/00 C07K017/00.

☐ 108. US 6344202B. Immunogen for protection against Chlamydia contains non-replicative vector - expressing major outer membrane protein, provides cellular and recall responses, specifically against C. trachomatis. BRUNHAM, R C. A61K031/70 A61K038/00 A61K039/00 A61K039/118 A61K039/38 A61K048/00 A61P031/04 C07H019/00 C07H021/02 C07K001/00 C07K014/295 C12N015/00 C12N015/09 C12N015/31 C12N015/63.

☐ 109. WO 9426900A. New hybrid picornaviruses expressing chlamydial epitopes - used to develop prods. for vaccination, diagnosis, treatment of chlamydial infections and prodn. of immunological

reagents. CALDWELL, H D, et al. A61K039/118 A61K039/13 C12N007/00 C12N015/31 C12N015/62 C12N015/86 C12P021/08 G01N033/571.

Generate Collection Print

Terms	Documents
L9 and chlamyd$	109

Prev Page Next Page Go to Doc

US-PAT-NO: 6838085
DOCUMENT-IDENTIFIER: US 6838085 B2

TITLE: DNA immunization against Chlamydia infection

DATE-ISSUED: January 4, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Brunham; Robert C.	Winnipeg			CA

US-CL-CURRENT: 424/263.1; 424/185.1, 435/252.3, 435/471, 530/350, 530/389.5, 530/412, 536/22.1, 536/23.1, 536/23.7

CLAIMS:

What I claim is:

1. A non-replicating vector, comprising: a nucleotide sequence encoding a region comprising at least one of the conserved domains 2, 3 and 5 of a major outer membrane protein of a strain of Chlamydia, and a promoter sequence operatively coupled to said nucleotide sequence for expression of said at least one conserved domain in a host.

2. The vector of claim 1 wherein said nucleotide sequence encoding the conserved domain 2 and/or 3 further includes a nucleotide sequence encoding a variable domain of the major outer membrane protein immediately downstream of the conserved domain.

3. The vector of claim 1 wherein said nucleotide sequence encodes the conserved domain 5 of the outer membrane protein.

4. The vector of claim 1 wherein said promoter sequence is the cytomegalovirus promoter.

5. The vector of claim 1 wherein said non-replicating vector comprises plasmid pcDNA3 containing said promoter sequence and into wherein said nucleotide sequence is inserted in operative position to said promoter sequence.

6. The vector of claim 5 wherein said strain of Chlamydia is a strain producing chlamydial infectious of the lung.

7. The vector of claim 5 wherein said strain of Chlamydia is a strain of Chlamydia trachomatis.

US-PAT-NO: 6696421
DOCUMENT-IDENTIFIER: US 6696421 B2

TITLE: DNA immunization against chlamydia infection

DATE-ISSUED: February 24, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Brunham; Robert C.	Winnipeg			CA

US-CL-CURRENT: 514/44; 424/184.1, 424/263.1, 435/320.1, 435/69.1

CLAIMS:

I claim:

1. An immunogenic composition for intranasal or intramuscular administration to a host for the generation in the host of a protective immune response to a major outer membrane protein (MOMP) of a strain of Chlamydia trachornatis or Chlamydia pneumoniae, comprising a non-replicating vector suitable for DNA vaccine use, comprising: a nucleotide sequence encoding said MOMP or an N-terminal fragment of approximately half full-length MOMP, and a cyomegalovirus promoter sequence operatively coupled to said nucleotide sequence for expression of said MOMP in the host; and a pharmaceutically-acceptable carrier therefor.

2. The immunogenic composition of claim 1 wherein said nucleotide sequence encodes full-length MOMP.

3. The immunogenic composition of claim 1 wherein said strain of Chlamydia is a strain of Chlamydia trachomatis.

4. The immunogenic composition of claim 3 wherein said non-replicating vector comprises plasmid pcDNA3 containing said promoter sequence and into which said nucleotide sequence is inserted in operative relation to said promoter sequence.

5. The immunogenic composition of claim 1 wherein said immune response is predominantly a cellular immune response.

6. The immunogenic composition of claim 1 wherein said nucleotide sequence encodes said MOMP which stimulates a recall immune response following exposure to wild-type Chlamydia.

7. A method of immunizing a host against disease caused by infection with a strain of Chlamydia trachomatis or Chlamydia pneunioniae, which comprises administering to said host intranasally or intramuscularly an effective amount of a non-replicating vector comprising: a nucleotide sequence encoding a major outer membrane protein (MOMP) of a strain of Chlamydia trachomatis or Chlamydia pneumoniae or an N-terminal fragment of approximately half the full-length MOMP, and a promoter sequence operatively coupled to said nucleotide sequence for expression of said MOMP in the host.

8. The method of claim 7 wherein said nucleotide sequence encodes full-length MOMP.

9. The method of claim 7 wherein said nucleotide sequence encodes an N-terminal fragment of approximately half of full length MOMP.

10. The method of claim 7 wherein said promoter sequence is a cytomegalovirus promoter.

11. The method of claim 7 wherein said strain of Chlamydia is a strain of Chlamydia trachomatis.

12. The method of claim 7 wherein said non-replicating vector comprises plasmid pcDNA3 containing said promoter into which said nucleotide sequence is inserted in operative relation to said promoter sequence.

13. The method of claim 7 wherein said immune response is predominantly a cellular immune response.

14. The method of claim 7 wherein said nucleotide sequence encodes said MOMP which stimulates a recall immune response following exposure to wild-type Chlamydia.

15. The method of claim 7 wherein said non-replicating vector is administered intranasally.

16. A method of using a gene encoding a major outer membrane protein (MOMP) of a strain of Chlamydia trachomatis or Chlamycha pneumoniae or an N-terminal fragment of approximately half of the full-length MOMP, which comprises: isolating said gene, operatively linking said gene to at least one control sequence to produce a non-replicating vector, said control sequence directing expression of said MOMP or fragment thereof when introduced into a host to produce an immune response to said MOMP or fragment thereof, and introducing said vector into a host intranasally or intramuscularly.

17. The method of claim 16 wherein said gene encoding MOMP encodes full length MOMP.

18. The method of claim 16 wherein said gene encoding MOMP encodes an N-terminal fragment of approximately half of full-length MOMP.

19. The method of claim 16 wherein said control sequence is a cytomegalovirus promoter.

20. The method of claim 16 wherein said strain of Chlamydia is a strain of Chlamydia trachomatis.

21. The method of claim 16 wherein said non-replicating vector comprises plasmid pcDNA3 containing said control sequence into which said gene encoding MOMP is inserted in operative relation to said control sequence.

22. The method of claim 16 wherein said immune response is predominantly a cellular immune response.

23. The method of claim 16 wherein said gene encodes said MOMP which

stimulates a recall immune response following exposure to wild-type Chlamydia.

24. The method of claim 16 wherein said vector is introduced into said host intranasally.

L8: Entry 32 of 99 File: USPT Feb 3, 2004

US-PAT-NO: 6686339
DOCUMENT-IDENTIFIER: US 6686339 B1

TITLE: Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia

DATE-ISSUED: February 3, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Murdin; Andrew D.	Newmarket			CA
Dunn; Pamela L.	Mississauga			CA
Oomen; Raymond P.	Schomberg			CA

US-CL-CURRENT: 514/44; 424/93.2, 435/320.1, 536/23.1, 536/23.2, 536/24.1

CLAIMS:

What we claim is:

1. An expression cassette comprising an isolated nucleic acid molecule placed under the control of elements required for expression of said nucleic acid molecule, said isolated nucleic acid molecule comprising a polynucleotide sequence encoding an amino acid sequence selected from the group consisting of: (a) an amino acid sequence as set forth in SEQ ID NO: 3; and (b) a fragment of the sequence in (a), said fragment comprising at least 12 amino acids and being capable of inducing an immune response against Chlamydia.

2. The expression cassette according to claim 1 wherein, in (b), said fragment comprises at least 20 amino acids.

3. The expression cassette according to claim 1 wherein, in (b), said fragment comprises at least 50 amino acids.

4. The expression cassette according to claim 1 wherein, in (b), said fragment comprises at least 75 amino acids.

5. The expression cassette according to claim 1 wherein, in (b), said fragment comprises at least 100 amino acids.

6. The expression cassette according to claim 1 wherein, in (b), said amino acid sequence retains the specific antigenicity of SEQ ID NO: 3.

7. The expression cassette according to claim 1, said nucleic acid molecule comprising a polynucleotide sequence encoding the amino acid sequence as set forth in SEQ ID NO: 3.

8. The expression cassette according to claim 1, wherein said polynucleotide sequence comprises the sequence set forth in SEQ ID NO: 1 or 2.

9. An expression vector comprising the expression cassette of claim 1.

10. A vaccine vector comprising an isolated nucleic acid molecule placed under the control of elements required for expression of said isolated nucleic acid molecule, said nucleic acid molecule comprising a polynucleotide sequence encoding an amino acid sequence selected from the group consisting of: (a) an amino acid sequence as set forth in SEQ ID NO: 3; and (b) a fragment of the sequence in (a), said fragment comprising at least 12 amino acids and being capable of inducing an immune response against Chlamydia.

11. The vaccine vector according to claim 10 wherein, in (b), said fragment comprises at least 20 amino acids.

12. The vaccine vector according to claim 10 wherein, in (b), said fragment comprises at least 50 amino acids.

13. The vaccine vector according to claim 10 wherein, in (b), said fragment comprises at least 75 amino acids.

14. The vaccine vector according to claim 10 wherein, in (b), said fragment comprises at least 100 amino acids.

15. The vaccine vector according to claim 10 wherein, in (b), said amino acid sequence retains the specific antigenicity of SEQ ID NO: 3.

16. The vaccine vector according to claim 10, said nucleic acid molecule comprising a polynucleotide sequence encoding the amino acid sequence as set forth in SEQ ID NO: 3.

17. The vaccine vector according to claim 10, wherein said polynucleotide sequence comprises the sequence set forth in SEQ ID NO: 1 or 2.

18. The vaccine vector according to claim 10 wherein the elements required for expression include a promoter.

19. The ~~vaccine vector~~ according to claim 18 wherein the promoter is a cytomegalovirus promoter.

20. The vaccine vector according to claim 19, which is a plasmid vector.

21. The vaccine vector of claim 20 wherein said plasmid vector has the identifying characteristics of plasmid pCAI115, as shown in FIG. 3.

22. An imunogenic composition comprising an isolated nucleic acid molecule comprising a polynucleotide sequence encoding an amino acid sequence selected from the group consisting of: (a) an amino acid sequence as set forth in SEQ ID NO: 3; and (b) a fragment of the sequence in (a), said fragment comprising at least 12 amino acids and being capable of inducing an immune response against Chlamydia.

23. An immunogenic composition comprising a vaccine vector according to claim 10.

24. An immunogenic composition comprising a vaccine vector according to claim 11.

25. An immunogenic composition comprising a vaccine vector according to claim

12.

26. An immunogenic composition comprising a vaccine vector according to claim 13.

27. An immunogenic composition comprising a vaccine vector according to claim 14.

28. An immunogenic composition comprising a vaccine vector according to claim 15.

29. An immunogenic composition comprising a vaccine vector according to claim 16.

30. An immunogenic composition comprising a vaccine vector according to claim 17.

31. A method for inducing an immune response against Chlamydia, comprising administering to a host an effective amount of an immunogenic composition according to claim 23.

32. A method for inducing an immune response against Chlamydia, comprising administering to a host an effective amount of an immunogenic composition according to claim 24.

33. A method for inducing an immune response against Chlamydia, comprising administering to a host an effective amount of an immunogenic composition according to claim 25.

34. A method for inducing an immune response against Chlamydia, comprising administering to a host an effective amount of an immunogenic composition according to claim 26.

35. A method for inducing an immune response against Chlamydia, comprising administering to a host an effective amount of an immunogenic composition according to claim 27.

36. A method for inducing an immune response against Chlamydia, comprising administering to a host an effective amount of an immunogenic composition according to claim 28.

37. A method for inducing an immune response against Chlamydia, comprising administering to a host an effective amount of an immunogenic composition according to claim 29.

38. A method for inducing an immune response against Chlamydia, comprising administering to a host an effective amount of an immunogenic composition according to claim 30.

L8: Entry 42 of 99 File: USPT Aug 29, 2000

US-PAT-NO: 6110898
DOCUMENT-IDENTIFIER: US 6110898 A

TITLE: DNA vaccines for eliciting a mucosal immune response

DATE-ISSUED: August 29, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Malone; Robert W.	Baltimore	MD		
Malone; Jill G.	Baltimore	MD		

US-CL-CURRENT: 514/44; 424/204.1, 424/234.1, 424/256.1, 424/93.1, 435/455, 435/6, 435/69.1, 435/91.1

CLAIMS:

What is claimed is:

1. A method for inducing a mucosal immune response in a host comprising locally administering to said host an antigen-encoding polynucleotide preparation, whereby administration of said polynucleotide preparation is specifically targeted to mucosal inductor sites.

2. The method of claim 1, wherein said host is a mammal.

3. The method of claim 2, wherein said mammal is a human.

4. The method of claim 1, wherein said antigen-encoding polynucleotide preparation is a viral vector.

5. The method of claim 4, wherein said viral vector contains heterologous regions which encode for epitopic regions of at least one immunogenic protein.

6. The method of claim 5, wherein said immunogenic protein is encoded by a virus selected from the group consisting of Human Papalloma Virus, Herpes Simplex Virus, and Human Immunodeficiency Virus.

7. The method of claim 6, wherein said virus is Human Papalloma Virus.

8. The method of claim 5, wherein said immunogenic protein is the Human Papilloma Virus major viral capsid protein L1.

9. The method of claim 6, wherein said virus is Herpes Simplex Virus.

10. The method of claim 5, wherein said immunogenic protein is the Herpes Simplex Virus immediate early protein ICP 27.

11. The method of claim 6, wherein said virus is Human Immunodeficiency Virus.

12. The method of claim 5, wherein said immunogenic protein is the all or part of the Human Immunodefieiency Virus envelope, gag, nef, or tat proteins.

13. The method of claim 5, wherein said viral vector includes a recombinant alphavirus vector system.

14. The method of claim 1, wherein said antigen-encoding polynucleotide preparation is derived from a prokaryote.

15. The method of claim 14, wherein said prokaryote contains heterologous genetic regions which encode for epitopic regions of at least one immunogenic protein.

16. The method of claim 14, wherein said prokaryote is selected from the group consisting of Helicobacter Pylorii and Chlamydia trachomatis.

17. The method of claim 15, wherein said immunogenic protein is all or part of the Helicobacter Pylorii urease protein.

18. The method of claim 15, wherin said immunogenic protein is all or part of the Chlamydia trachomatis major outer membrane protein.

19. The method of claim 1, wherein said mucosal inductor sites are selected from the group consisting of Waldeyer's ring, Peyer's patches, gut-associated lymphoid tissues, bronchial associated lymphoid tissues, nasal-associated lymphoid tissues, genital-associated lymphoid tissues, and tonsils.

20. A method for polynucleotide delivery to the mucosal tissue of a host comprising locally administering to said host an antigen-encoding polynucleotide preparation, whereby administration of said polynucleotide preparation is specifically targeted to mucosal inductor sites.

21. The method of claim 20, wherein said host is a mammal.

22. The method of claim 21, wherein said mammal is a human.

23. The method of claim 20, wherein said antigen-encoding polynucleotide preparation is a viral vector.

24. The method of claim 23, wherein said viral vector contains heterologous regions which encode for epitopic regions of at least one immunogenic protein.

25. The method of claim 24, wherein said immunogenic protein is encoded by a virus selected from the group consisting of Human Papalloma Virus, Herpes Simplex Virus, and Human Immunodeficiency Virus.

26. The method of claim 25, wherein said virus is Human Papalloma Virus.

27. The method of claim 24, wherein said immunogenic protein is the Human Papilloma Virus major viral capsid protein L1.

28. The method of claim 25, wherein said virus is Herpes Simplex Virus.

29. The method of claim 24, wherein said immunogenic protein is the Herpes

Simplex Virus immediate early protein ICP 27.

30. The method of claim 25, wherein said virus is Human Immunodeficiency Virus.

31. The method of claim 24, wherein said immunogenic protein is the all or part of the Human Immunodefieiency Virus envelope, gag, nef, or tat proteins.

32. The method of claim 1, wherein said antigen-encoding polynucleotide preparation is derived from a prokaryote.

33. The method of claim 32, wherein said prokaryote contains heterologous genetic regions which encode for epitopic regions of at least one immunogenic protein.

34. The method of claim 32, wherein said prokaryote is selected from the group consisting of Helicobacter Pylorii and Chlamydia trachomatis.

35. The method of claim 33, wherein said immunogenic protein is all or part of the Helicobacter Pylorii urease protein.

36. The method of claim 33, wherin said immunogenic protein is all or part of the Chlamydia trachomatis major outer membrane protein.

37. The method of claim 23, wherein said viral vector includes a recombinant alphavirus vector system.

38. The method of claim 20, wherein said mucosal inductor sites are selected from the group consisting of Waldeyer's ring, Peyer's patches, gut-associated lymphoid tissues, bronchial associated lymphoid tissues, nasal-associated lymphoid tissues, genital-associated lymphoid tissues, and tonsils.

Generate Collection | Print

Search Results - Record(s) 1 through 50 of 99 returned.

☐ 1. 20050069942. 01 Nov 04. 31 Mar 05. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin, Andrew D., et al. 435/6; 435/252.3 435/320.1 435/69.3 530/350 536/23.7 C12Q001/68 C07H021/04 C07K014/295 C12N015/74.

☐ 2. 20050065106. 10 Sep 04. 24 Mar 05. Immunogenic compositions for protection against Chlamydial infection. Murdin, Andrew D., et al. 514/44; A61K048/00.

☐ 3. 20050037019. 11 Aug 03. 17 Feb 05. Vaccines for Chlamydia psittaci infections. Kousoulas, Konstantin G., et al. 424/190.1; 424/263.1 A61K039/02 A61K039/118.

☐ 4. 20050002944. 29 Dec 03. 06 Jan 05. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin, Andrew D., et al. 424/184.1; A61K039/00 A61K039/38.

☐ 5. 20040228874. 14 Jan 04. 18 Nov 04. Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia. Murdin, Andrew D., et al. 424/190.1; 435/252.3 435/320.1 435/6 435/69.3 530/350 536/23.7 C12Q001/68 C07H021/04 A61K039/02.

☐ 6. 20040192591. 24 Nov 03. 30 Sep 04. Composition for treating Chlamydia infections and method for identifying same. Wooters, Joseph L., et al. 514/9; 435/32 A61K038/12 C12Q001/18.

☐ 7. 20040181036. 04 Dec 03. 16 Sep 04. Mutant forms of cholera holotoxin as an adjuvant. Green, Bruce A, et al. 530/350; A61K039/106 C07K001/00 C07K014/00 C07K017/00.

☐ 8. 20040180147. 30 Oct 03. 16 Sep 04. Direct micro-patterning of lipid bilayers using UV light and selected uses thereof. Parikh, Atul Navinchandra, et al. 427/558; 427/282 B05D001/32 B05D003/06.

☐ 9. 20040176571. 04 Dec 03. 09 Sep 04. Mutant forms of cholera holotoxin as an adjuvant. Green, Bruce A., et al. 530/350; A61K039/106 C07K001/00 C07K014/00 C07K017/00.

☐ 10. 20040131624. 16 Dec 03. 08 Jul 04. Secreted chlamydia polypeptides and method for identifying such polypeptides by their secretion by a type lll secretion pathway of a gram-negative bacteria.. Subtil, Agathe, et al. 424/184.1; A61K039/00 A61K039/38.

☐ 11. 20040101867. 15 May 03. 27 May 04. Use of microbial dna sequences for the identification of human diseases. Fritzsche, Markus. 435/6; 536/23.7 C12Q001/68 C07H021/04.

☐ 12. 20040052804. 19 Aug 03. 18 Mar 04. Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria. Arumugham, Rasappa G., et al. 424/184.1; A61K039/00 A61K039/38.

☐ 13. 20040043032. 12 May 03. 04 Mar 04. Vaccine. McKenzie, Ian Farquhar Campbell, et al. 424/184.1; A61K039/00 A61K039/38.

☐ 14. 20040037846. 01 Aug 03. 26 Feb 04. Chlamydia pmp proteins, gene sequences and uses thereof. Jackson, W. James. 424/190.1; 435/252.3 435/320.1 435/6 435/69.3 530/350 536/23.7 C07K014/295 C12Q001/68 C07H021/04 A61K039/02 C12P021/02 C12N001/21.

☐ 15. 20030170259. 27 Oct 99. 11 Sep 03. CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF. MURDIN, ANDREW D., et al. 424/190.1; A61K039/02.

☐ 16. 20030157124. 20 Dec 02. 21 Aug 03. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin, Andrew D., et al. 424/190.1; 435/252.3 435/320.1 435/69.3 530/350 536/23 .7 A61K039/02 C07H021/04 C07K014/295 C12P021/02 C12N001/21 C12N015/74.

☐ 17. 20030138434. 13 May 02. 24 Jul 03. Agents for enhancing the immune response. Campbell, Robert L., et al. 424/184.1; A61K039/00.

☐ 18. 20030045702. 14 Dec 01. 06 Mar 03. Secreted Chlamydia polypeptides and method for identifying such polypeptides by their secretion by a type III secretion pathway of a gram-negative bacteria. Subtil, Agathe, et al. 536/23.7; 424/190.1 435/252.3 435/320.1 435/69.3 530/350 A61K039/02 C07H021/04 C12N001/21 C12P021/02 C07K014/295.

☐ 19. 20020142001. 07 Jan 02. 03 Oct 02. DNA immunization against Chlaymdia infection. Brunham, Robert C.. 424/184.1; A61K039/00 A61K039/38.

☐ 20. 20020136742. 28 Aug 98. 26 Sep 02. VACCINES FOR CHLAMYDIA PSITTACI INFECTIONS. KOUSOULAS, KONSTANTIN G., et al. 424/263.1; A61K039/118.

☐ 21. 20020131982. 20 Aug 98. 19 Sep 02. ISCOM OR ISCOM-MATRIX COMPRISING A MUCUS TARGETTING SUBSTANCE AND OPTIONALLY, AN ANTIGEN. MOREIN, BROR, et al. 424/232.1; A61K039/275 A61K039/285.

☐ 22. 20020110542. 12 Aug 99. 15 Aug 02. DNA IMMUNIZATION AGAINST CHLAMYDIA INFECTION. BRUNHAM, ROBERT C.. 424/93.2; 424/263.1 424/93.21 435/320.1 435/69.1 514/44 A61K048/00 A61K039/118.

☐ 23. 20020102270. 08 Feb 01. 01 Aug 02. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin, Andrew D., et al. 424/190.1; 435/183 435/252.3 435/320.1 435/69.3 514/44 536/23.7 A61K048/00 C07H021/04 C12N009/00 A61K039/02 C12N001/21 C12P021/02.

☐ 24. 20020099188. 22 Dec 00. 25 Jul 02. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin, Andrew D., et al. 536/23.1; C07H021/02 C07H021/04.

☐ 25. 20020094340. 01 Dec 99. 18 Jul 02. CHLAMYDIA ANTIGENS AND CORRESPONDING DNA THEREOF. MURDIN, ANDREW D., et al. 424/263.1; A61K039/118.

☐ 26. 20020077288. 22 May 01. 20 Jun 02. Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid beta for induction of an immune response to amyloid beta and amyloid deposits. Frangione, Blas, et al. 514/12; 514/13 514/14 530/324 530/326 530/327 A61K038/16 C07K014/00.

☐ 27. 20010041788. 28 Dec 00. 15 Nov 01. Cytotoxic T lymphocyte epitopes of the major outer membrane protein of chlamydia trachomatis. DeMars, Robert I., et al. 530/328; 536/23.7 A61K038/00 C07H021/04 C07K005/00 C07K007/00 C07K016/00 C07K017/00 A61K038/04.

☐ 28. 20010002421. 18 Feb 98. 31 May 01. METHODS FOR IN VITRO SUSCEPTIBILITY TESTING OF CHLAMYDIA. STRATTON, CHARLES W, et al. 536/23.1; 435/6 536/24.3 536/24.32 C07H021/04 C12Q001/68 C07H021/04.

☐ 29. 6872814. 27 Oct 99; 29 Mar 05. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin; Andrew D., et al. 536/23.7; 424/184.1 424/234.1 424/263.1 435/252.3 435/320.1 435/69.3 435/71.1 435/71.2 536/23.1 536/23.4. C07H02104 C12N01500 C12N05909 A61K039118 A61K03902.

☐ 30. 6838085. 07 Jan 02; 04 Jan 05. DNA immunization against Chlamydia infection. Brunham; Robert C.. 424/263.1; 424/185.1 435/252.3 435/471 530/350 530/389.5 530/412 536/22.1 536/23.1 536/23.7. A61K039/118 A61K039/00 C07K001/00 C07H019/00 C07H021/02.

☐ 31. 6696421. 12 Aug 99; 24 Feb 04. DNA immunization against chlamydia infection. Brunham; Robert C.. 514/44; 424/184.1 424/263.1 435/320.1 435/69.1. A61K048/00 A61K039/00 A61K039/118 C12N015/63 C12N015/00.

☐ 32. 6686339. 15 Jun 01; 03 Feb 04. Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia. Murdin; Andrew D., et al. 514/44; 424/93.2 435/320.1 536/23.1 536/23.2 536/24.1. A61K048/00 A61K035/66 C12N015/63 C07H021/04.

☐ 33. 6653461. 28 Dec 00; 25 Nov 03. Cytotoxic T lymphocyte epitopes of the major outer membrane protein of Chlamydia trachomatis. DeMars; Robert I., et al. 536/23.1; 424/184.1 424/200.1 435/320.1 435/91.2 530/300 530/328 530/350. C07H021/02 C07H021/04 C07K016/00.

☐ 34. 6649370. 26 Oct 99; 18 Nov 03. Chlamydia antigens and corresponding DNA fragments and uses thereof. Murdin; Andrew D., et al. 435/69.1; 435/252.3 435/320.1 435/325 536/23.7. C12P021/06 C12N001/20 C12N015/00 C12N005/00 C07H021/04.

☐ 35. 6605287. 28 Aug 98; 12 Aug 03. Vaccines for Chlamydia psittaci infections. Kousoulas; Konstantin G., et al. 424/263.1; 424/184.1 424/185.1 514/2 530/350 530/389.5 530/412 530/825. A61K039/118 A61K039/00 A61K031/00 C07K004/04.

☐ 36. 6521745. 20 Aug 99; 18 Feb 03. Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia. Murdin; Andrew D., et al. 536/23.1; 536/24.3. C07H021/04.

☐ 37. 6344202. 07 Apr 98; 05 Feb 02. DNA immunization against chlaymdia infection. Brunham; Robert C.. 424/263.1; 424/185.1 530/350 530/389.5 530/412 536/22.1 536/23.1 536/23.7. A61K039/118 A61K039/00 C07K001/00 C07H019/00 C07H021/02.

☐ 38. 6258532. 18 Feb 98; 10 Jul 01. Methods for in vitro susceptibility testing of chlamydia. Stratton; Charles W., et al. 435/6; 435/23 435/32 435/34 435/7.36 435/91.2 536/23.7. C12Q001/68 C12Q001/37 C12Q001/18 G01N033/571 C12P019/34.

☐ 39. 6235290. 11 Jul 97; 22 May 01. DNA immunization against chlaymdia infection. Brunham; Robert C.. 424/263.1; 424/185.1 530/350 530/389.5 530/412. A61K039/118 A61K039/00 C07K001/00 C07K016/00.

☐ 40. 6225443. 17 Apr 00; 01 May 01. Cytotoxic T lymphocyte epitopes of the major outer membrane protein of chlamydia trachomatis. DeMars; Robert I., et al. 530/328; 435/320.1 435/6 435/91.2 530/300 530/350 536/23.1 536/24.32. C07K016/00.

☐ 41. 6191259. 19 May 99; 20 Feb 01. Cytotoxic T lymphocyte epitopes of the major outer membrane protein of chlamydia trachomatis. DeMars; Robert I., et al. 530/350; 424/184.1 435/6

530/300 530/326 530/328 536/23.1. C07K001/00.

☐ 42. 6110898. 23 May 97; 29 Aug 00. DNA vaccines for eliciting a mucosal immune response. Malone; Robert W., et al. 514/44; 424/204.1 424/234.1 424/256.1 424/93.1 435/455 435/6 435/69.1 435/91.1. A61K048/00 C17N015/00 C12Q001/70.

☐ 43. 6001372. 25 Aug 95; 14 Dec 99. Antigenic peptides of Chlamydia trachomatis. DeMars; Robert I., et al. 424/263.1; 424/184.1 424/185.1 424/190.1 424/234.1 530/326 530/328 530/350. A61K039/00 A61K039/02 A61K038/00 A61K038/04.

☐ 44. 5843446. 07 Jun 95; 01 Dec 98. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines. Ladd; Anna Efim, et al. 424/184.1; 424/185.1 424/195.11 424/811. A61K039/00 A61K039/38 A61K039/385 A61K039/395.

☐ 45. 5770714. 06 Jun 95; 23 Jun 98. Chlamydia major outer membrane protein. Agabian; Nina, et al. 536/23.1; 435/254.11 435/254.2 435/320.1 435/6 435/69.1 435/91.2 530/300 530/350 536/24.3 536/24.32 536/24.33. C07H021/02 C07H021/04 C07K005/00 C07K013/00.

☐ 46. 5541057. 10 Jun 93; 30 Jul 96. Methods for detection of an analyte. Bogart; Gregory R., et al. 435/5; 356/369 359/540 359/581 359/585 422/55 422/57 422/58 435/287.2 435/6 435/7.21 435/7.22 435/7.23 435/7.32 435/7.34 435/808 436/164 436/513 436/524 436/525 436/527 436/531 436/805. C12Q001/70 G01N033/53 G01N033/543 G01N021/00.

☐ 47. 5516638. 27 Jun 94; 14 May 96. Immunoassays for the detection of antibodies to Chlamydia trachomatisi in the urine.. Urnovitz; Howard B., et al. 435/7.32; 435/7.36 435/7.92 435/7.93 435/7.94 435/7.95 436/518 436/530 436/531 436/534. G01N033/543 G01N033/569 G01N033/571.

☐ 48. 4427782. 03 Mar 81; 24 Jan 84. Isolation of principal outer membrane protein and antigen of Chlamydia trachomatis. Caldwell; Harlan D., et al. 436/542; 435/7.36 435/7.92 435/7.93 435/961 436/543 436/544 436/545 436/546 436/547 436/811 530/370 530/389.5 530/417 530/423 530/425 530/806 530/825. G01N033/56 G01N033/58 G01N033/60 C07G007/00.

☐ 49. JP408038192A. 03 Aug 94. 13 Feb 96. MONOCLONAL ANTIBODY-FORMING CELL, PRODUCTION THEREOF, MONOCLONAL ANTIBODY AND PRODUCTION OF THE SAME. BABA, KENZO, et al. C12P021/08; C07K016/00 C12N005/10 C12N015/02.

☐ 50. JP406116285A. 07 Oct 92. 26 Apr 94. PEPTIDE, REAGENT FOR DIAGNOSING INFECTIOUS DISEASE WITH CHLAMYDIA TRACHOMATIS AND METHOD FOR PURIFYING CELL OF CHLAMYDIA TRACHOMATIS OR SUBSTANCE DERIVED FROM BACTERIAL CELL. KAWAGOE, KIYOTAKA, et al. C07K007/06; C12N001/20 C12P021/00 G01N033/53 G01N033/569 G01N033/571.

Generate Collection | Print

Terms	Documents
L7 and (mammal$ or animal$ or eukaryote or eukaryotic or eucaryote or eucaryotic or cho or human or fibroblast).ti,ab,clm.	99

Prev Page Next Page Go to Doc#

L5: Entry 6 of 7 File: USPT Mar 29, 2005

US-PAT-NO: 6872814
DOCUMENT-IDENTIFIER: US 6872814 B2

TITLE: Chlamydia antigens and corresponding DNA fragments and uses thereof

DATE-ISSUED: March 29, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Murdin; Andrew D.	Ontario			CA
Oomen; Raymond P.	Ontario			CA
Dunn; Pamela L.	Ontario			CA

US-CL-CURRENT: 536/23.7; 424/184.1, 424/234.1, 424/263.1, 435/252.3, 435/320.1, 435/69.3, 435/71.1, 435/71.2, 536/23.1, 536/23.4

CLAIMS:

What is claimed is:

1. An isolated polynucleotide from a strain of Chlamydia selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1; and (b) a polynucleotide which hybridizes under stringent hybridizing conditions of 6.times.SSC containing 50% formamide at 42.degree. C. with the polynucleotide comprising the nucleotide sequence of SEQ ID NO:1.

2. The polynucleotide of claim 1, linked to a second nucleotide sequence wherein the polynucleotide encodes a fusion polypeptide.

3. The polynucleotide of claim 2 wherein the fusion polypeptide is a heterologous signal peptide.

4. The polynucleotide of claim 2 wherein the polynucleotide encodes a polypeptide comprising the amino acid sequence of SEQ ID NO: 2.

5. An expression cassette, comprising the polynucleotide of claim 1 operably linked to a promoter.

6. An expression vector, comprising the expression cassette of claim 5.

7. An isolated host cell, comprising the expression cassette of claim 5.

8. The host cell of claim 7, wherein said host cell is a prokaryotic cell.

9. The host cell of claim 7, wherein said host cell is a eukaryotic cell.

10. A vaccine vector, comprising the expression cassette of claim 5.

11. The vaccine vector of claim 10, wherein said vector is in a pharmaceutically acceptable excipient.

12. A pharmaceutical composition, comprising an immunologically effective amount of the vaccine vector of claim 10.

13. The host cell of claim 9, wherein said eukaryotic cell is a mammalian cell.

14. The host cell of claim 13, wherein said mammalian cell is a human cell.

15. The vaccine vector of claim 10, wherein said vector is a viral live vaccine vector or a bacterial live vaccine vector.

16. The vaccine vector of claim 15, wherein said viral live vaccine vector is selected from the group consisting of: adenoviruses, alphavirus, and poxviruses.

17. The vaccine vector of claim 15, wherein said bacterial live vaccine vector is selected from the group consisting of: Shigella, Salmonella, Vibrzo cholerae, Lactobacillus, Bacille bilie de Calmette-Guerin, and Streptococcus.

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 1 of 1 returned.

☐ 1. Document ID: US 6872814 B2

L1: Entry 1 of 1 File: USPT Mar 29, 2005

US-PAT-NO: 6872814
DOCUMENT-IDENTIFIER: US 6872814 B2

TITLE: Chlamydia antigens and corresponding DNA fragments and uses thereof

DATE-ISSUED: March 29, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Murdin; Andrew D.	Ontario			CA
Oomen; Raymond P.	Ontario			CA
Dunn; Pamela L.	Ontario			CA

ASSIGNEE-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY	TYPE CODE
Aventis Pasteur Limited	Toronto			CA	03

APPL-NO: 09/ 428122 [PALM]
DATE FILED: October 27, 1999

PARENT-CASE:
RELATED U.S. APPLICATION The present patent application claims priority to the following United States provisional patent applications: U.S. Ser. Nos. 60/106,070, filed Oct. 29, 1998 and No. 60/122,066, filed Mar. 1, 1999, each incorporated herein by reference.

INT-CL: [07] C07H02104, C12N01500, C12N05909, A61K039118, A61K03902

US-CL-ISSUED: 536/23.7; 536/23.1, 536/23.4, 435/320.1, 435/252.3, 435/69.3, 435/71.1, 435/71.2, 424/263.1, 424/234.1, 424/184.1
US-CL-CURRENT: 536/23.7; 424/184.1, 424/234.1, 424/263.1, 435/252.3, 435/320.1, 435/69.3, 435/71.1, 435/71.2, 536/23.1, 536/23.4

FIELD-OF-SEARCH: 536/23.7, 536/23.4, 536/23.1, 536/24.3, 536/24.32, 424/184.1, 424/200.1, 424/263.1, 424/234.1, 424/320.1, 435/252.3, 435/71.1, 435/71.2, 435/69.3

PRIOR-ART-DISCLOSED:

U.S. PATENT DOCUMENTS